Trials / Unknown
UnknownNCT01951898
Effects of Montelukast on Airway Regulatory T Cells in Asthma
Effects of Montelukast on Airway Foxp3+ and CTLA4+CD25highCD4+ T Cells in Asthmatics
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Kurume University · Academic / Other
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Montelukast is one of anti-inflammatory agents and a good controller for the patients with asthma. The hypothesis of the study is that the Montelukast will have airway anti-inflammatory effects and up-regulated regulatory T cells functions in asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Montelukast | 10mg/day, once a daily after dinner, for 28dyas |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2013-12-01
- Completion
- 2015-05-01
- First posted
- 2013-09-27
- Last updated
- 2013-09-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01951898. Inclusion in this directory is not an endorsement.